TABLE 1.
Patient Characteristics for Each Data Set
| COMPARZ N51110 | ENESTnd N5846 | NCCN N5533 | BIOQOL and Q-Score N5286 | |
|---|---|---|---|---|
|
| ||||
| Randomized to Pazopanib or Sunitinib | Randomized to Nilotinib or Imatinib | Cross-Sectional, Prior Experience With Chemotherapy | Cross-Sectional | |
| Diagnosis | ||||
| Bladder | 31 (6%) | |||
| Brain | 50 (9%) | |||
| Breast | 52 (10%) | 804 (28%) | ||
| Colorectal | 50 (9%) | 439 (15%) | ||
| CML | 846 (100%) | |||
| Endometrial | ||||
| Head and neck | 49 (9%) | 411 (14%) | ||
| Hepatobiliary | 50 (9%) | |||
| Kidney | 1110 (100%) | 50 (9%) | ||
| Lung | 50 (9%) | 503 (17%) | ||
| Lymphoma | 50 (9%) | 199 (7%) | ||
| Ovarian | 51 (10%) | |||
| Prostate | 50 (9%) | 205 (7%) | ||
| Other/unknown | 323 (11%) | |||
| Age, y | ||||
| Range | 18–88 | 18–85 | 24–88 | 17–99 |
| Median | 61 | 46 | 59 | 58 |
| Female sex | 297 (27%) | 355 (42%) | 257 (48%) | 1552 (54%) |
| KPS | ||||
| 70 or 80 | 271 (24%) | |||
| 90 or 100 | 839 (76%) | |||
| ECOG PS | ||||
| 0 | 122 (23%) | 933 (32%) | ||
| 1 | 258 (48%) | 826 (29%) | ||
| 32 | 153 (29%) | 1119 (39%) | ||
Abbreviations: BIOQOL, Bilingual Intercultural Oncology Quality of Life; CML, chronic myelogenous leukemia; COMPARZ, Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma; ECOG PS, Eastern Cooperative Oncology Group performance status; ENESTnd, Evaluating Nilotinib Efficacy and Safety in Clinical Trials–Newly Diagnosed Patients; KPS, Karnofsky performance status; NCCN, National Comprehensive Cancer Network.